Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorZhejiang University
About this trial
Multimodal Thermal Therapy combined with targeted therapy and immunotherapy versus targeted therapy and immunotherapy alone for systemically untreated unresectable hepatocellular carcinoma (HCC)
Eligibility criteria
Qualifiers
• Age 18-80, regardless of gender;
Diagnosed with unresectable HCC by imaging or histology, BCLC stage B or C;
No prior systemic immunotherapy, chemotherapy, targeted therapy, or other systemic drug treatments for HCC;
Presence of an image-evaluable lesion intended for ablation without prior local ablation therapy, with the maximum diameter of the target tumor ≤5 cm;
Disqualifiers
• Invasion of the main portal vein;
Diffuse hepatocellular carcinoma;
Patients with a history or current diagnosis of brain metastases whose symptoms are not fully controlled (i.e., persistent or worsening symptoms, or requiring adjustments to symptomatic treatment to maintain symptom relief);
Extensive distant metastasis confirmed by imaging (e.g., chest/abdominal CT/MRI, whole-body bone scan, PET-CT, etc.), including but not limited to diffuse lung metastasis, multiple bone metastases, extensive abdominal/peritoneal metastasis, or other multi-organ metastases, where the investigator assesses that the extent of metastasis may compromise the safe administration of study treatment or affect efficacy and safety evaluations;
Trial design
Treatments tested in this trial
- Multimodal Thermal Therapy
- Targeted and Immune Drugs
Treatment groups
166 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov